Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Common Equity (2016 - 2025)

Historic Common Equity for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to $161.5 million.

  • Regenxbio's Common Equity fell 4643.55% to $161.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $161.5 million, marking a year-over-year decrease of 4643.55%. This contributed to the annual value of $259.7 million for FY2024, which is 1670.97% down from last year.
  • According to the latest figures from Q3 2025, Regenxbio's Common Equity is $161.5 million, which was down 4643.55% from $213.7 million recorded in Q2 2025.
  • Regenxbio's Common Equity's 5-year high stood at $764.3 million during Q4 2021, with a 5-year trough of $161.5 million in Q3 2025.
  • In the last 5 years, Regenxbio's Common Equity had a median value of $405.9 million in 2023 and averaged $430.7 million.
  • Per our database at Business Quant, Regenxbio's Common Equity soared by 10232.74% in 2021 and then plummeted by 4643.55% in 2025.
  • Quarter analysis of 5 years shows Regenxbio's Common Equity stood at $764.3 million in 2021, then plummeted by 32.46% to $516.2 million in 2022, then plummeted by 39.61% to $311.7 million in 2023, then fell by 16.71% to $259.7 million in 2024, then plummeted by 37.82% to $161.5 million in 2025.
  • Its Common Equity stands at $161.5 million for Q3 2025, versus $213.7 million for Q2 2025 and $274.2 million for Q1 2025.